Abeclib (Abemaciclib 200 mg) is a kinase inhibitor, which was initially approved by the FDA in 2017 and is used

In combination with endocrine therapy in adult patients who have been diagnosed with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive early breast cancer with a high risk of recurrence.
In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal patients with (HR positive and HER2-negative) advanced or metastatic breast cancer.
In combination with fulvestrant for the treatment of adult patients with (HR positive and HER2-negative) advanced or metastatic breast cancer with disease progression following endocrine therapy.
As a single therapy to treat (HR positive and HER2-negative) advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.

Abemaciclib 200 mg Tablet Mechanism of Action

Abeclib is a CDK4 and CDK6 protein kinase inhibitor that leads cancer cells to grow and multiply. Abeclib works by blocking their activities and helps slow down the growth and division of cancer cells.

Abemaciclib Tablet Dosage and Administration

Recommended dose of Abeclib in combination with fulvestrant, tamoxifen, or an aromatase inhibitor: 150 mg twice daily.
As a monotherapy, the standard recommended dose is 200 mg orally once daily.
The healthcare provider may reduce or interrupt the dose based on safety and tolerability.
Take the medication exactly as your healthcare provider tells you.
Abeclib may be taken with or without food.
Swallow the whole tablet; do not chew, crush, or split the tablet. Do not take a broken or damaged tablet.

Possible Side Effects of Abemaciclib 200 mg

Diarrhea: Abeclib can cause severe diarrhea associated with dehydration and infection. The healthcare provider will instruct patients to take antidiarrheal therapies, increase oral fluids, and inform the healthcare provider at the first sign of loose stool.

Neutropenia: The medication can cause a low blood cell count. The healthcare provider will perform a complete blood count test before starting treatment, every week for the first two months, and then monthly for the next two months, as clinically indicated.

Interstitial Lung Disease (ILD)/Pneumonitis: Severe and fatal cases of ILD/pneumonitis have been reported. Healthcare providers should monitor patients for clinical symptoms and radiology changes for ILD/pneumonitis. Treatment should be discontinued permanently if grade 3 or 4 ILD/pneumonitis is found.

Hepatotoxicity: Severe liver diseases have been observed during the treatment with Abeclib. Perform liver function tests before starting therapy, then weekly for the first two months, monthly for the next two months, and as clinically indicated.

Venous Thromboembolism: Observe patients for signs and symptoms of thrombosis and pulmonary embolism. If found, treat as medically appropriate.

Embryo-Fetal Toxicity: Abeclib can cause fetal harm to unborn children. Use proper contraception and an effective birth control method to avoid the risk.

Tell your health care provider before taking Abeclib 200 mg

Inform your healthcare provider if you

are taking other prescription, non-prescription medicines
have serious infections that are not healing for an extended period.
have liver problems, lung problems, and other major medical conditions.
have a blood disease that causes bleeding or bruising
have low platelet count, low red blood cell count, low white blood cell count
are pregnant or planning to become pregnant
are breastfeeding or planning to breastfeed.

Abemaciclib 200 mg price in Bangladesh

The price of abemaciclib 200 mg depends on the manufacturer. Abeclib (generic Abemaciclib), manufactured by Eskayef Pharmaceuticals Ltd., costs around $15 per unit for a 200 mg tablet. Price is variable and can be changed.

Why does Abeclib cause diarrhea?

Abemaciclib causes diarrhea because it inhibits CDK4 and CDK6 not only in cancer cells but also in rapidly dividing normal intestinal epithelial cells, disrupting their renewal and absorption, which leads to increased intestinal motility and fluid secretion.

How long does Abeclib work?

Abemaciclib works as long as it effectively controls cancer growth. Treatment continues until disease progression or unacceptable toxicity occurs. Its benefits can last months to years, depending on individual response, cancer type, and combination with other therapies.

How long does Abeclib stay in your system?

Abemaciclib stays in your system for about 5 to 6 days after the last dose. Its half-life is around 18 hours, meaning it takes several days for the drug to be mostly eliminated from the body.

What type of therapy is Abeclib?

Abeclib (Abemaciclib 200 mg) is a targeted therapy known as a CDK4/6 inhibitor. It specifically blocks cyclin-dependent kinases 4 and 6, which are enzymes that promote cancer cell growth and division, particularly in hormone receptor-positive (HR+), HER2-negative breast cancer.